A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) | MicrobiomeTrials← Back to trialsNCT07157254
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-10-13Est. Completion: 2030-01
Enrollment target: 60 participants Locations- Cedars Sinai Medical Center, Los Angeles, California, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Clinical Trial Site, Baltimore, Maryland, United States
- Clinical Trial Site, Kansas City, Missouri, United States
- Rare Disease Research, Hillsborough, North Carolina, United States
- Akron Children's Hospital, Akron, Ohio, United States
- UT Health Austin, Austin, Texas, United States
- Carum Research Inc., Dallas, Texas, United States
- Hospital Universitario Austral, Pilar, Buenos Aires, Argentina
- Hospital de Crianças César Pernetta e Hospital Pequeno Príncipe, Curitiba, Paraná, Brazil
- Casa dos Raros, Santa Cecília, Porto Alegre, Brazil
- Hopital de la Timone, Marseille, France
- Necker-Enfants Malades Hospital, Paris, France
- Sheba Medical Center, Ramat Gan, Israel
- Azienda Ospedaliera Universitaria Meyer IRCCS, Florence, Italy
- Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy
- Clinical Trial Site, Rome, Italy
Other microbiome trials you might be interested in
Angelman Syndrome
The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman …
Los Angeles, United StatesCompleted Feb 2029
Angelman Syndrome
The purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Ang…
Los Angeles, United StatesEst. completion Mar 31, 2028
Hospital de Santa Maria, Lisbon, PortugalHospital Santa Joao, Porto, PortugalClinical Trial Site, London, United KingdomUniversity of Oxford, Oxford, United Kingdom